Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmonary Hypertension
Biotech
Cash-strapped Quince finds salvation in reverse merger
Quince began seeking strategic alternatives after its lead candidate failed in a phase 3 trial for a rare pediatric neurodegenerative disease.
Darren Incorvaia
May 18, 2026 10:32am
Bayer scraps ph.1-stage hypertension, neuropathic pain drugs
May 12, 2026 5:07am
Keros ends hypertension trial over fluid buildups around heart
Jan 15, 2025 8:25am
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Sep 10, 2024 7:57am
Gossamer touts phase 2 win but investors are wary
Dec 6, 2022 11:09am
ECG-enhancing AI scores FDA breakthrough nod
May 27, 2022 11:27am
